Search Results

Mechanisms of Transcatheter Valve Degeneration

A translational perspective.

By Hacina Gill, BSc; David Meier, MD; Althea Lai, BSc; Geoffrey W. Payne, MSc, PhD; and Stephanie L. Sellers, MSc, PhD

Redo TAVR: Technical Considerations

Key concepts and risk management for procedural planning of redo TAVR.

By David Meier, MD; Stephane Fournier, MD, PhD; and Janarthanan Sathananthan, MBChB, MPH

Management of THV Degeneration

By Janarthanan Sathananthan, MD, and S. Jay Mathews, MD

Sirolimus-Eluting Cypher Stent

A standard of comparison for drug-eluting stents.

By Colin M. Barker, MD, and David E. Kandzari, MD

The FAME Trial

Fractional flow reserve for target revascularization in multivessel PCI.

By Eric Yamen, MBBS, FRACP, and David P. Lee, MD

Patient Selection for PFO Closure Based on the RoPE Study

Can a CHADS-like risk score help to predict who will benefit from PFO-specific therapy in the cryptogenic stroke population?

By David E. Thaler, MD, PhD, FAHA

Patent Foramen Ovale Closure for Cryptogenic Stroke

Developing a treatment strategy guided by clinical data.

By HoHai Van, MD, and Jonathan Tobis, MD

Radial Versus Femoral Access in PCI

An economic and quality analysis.

By Purushothaman Muthusamy, MD, and David H. Wohns, MD, FACC, FSCAI

The Emerging Role of Transcatheter Mitral Valve Implantation in Clinical Practice

An analysis of treatment options for mitral regurgitation and how TMVI can complement and extend the therapy armamentarium for MV disease.

By Andreas Schaefer, MD, MHBA, and Lenard Conradi, MD

Anticoagulation Management After Watchman Implantation

Current indications for antiplatelet agents and NOACs after Watchman implantation.

By Mathieu Lempereur, MD, and Adel Aminian, MD

Transcatheter Valve Therapies

By Ted E. Feldman, MD, FSCAI - Chief Medical Editor